Innocrin Pharmaceuticals, Inc.

Release Summary

Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in ER-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium.

Innocrin Pharmaceuticals, Inc.